| EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib S Kobayashi, TJ Boggon, T Dayaram, PA Jänne, O Kocher, M Meyerson, ... New England Journal of Medicine 352 (8), 786-792, 2005 | 4875 | 2005 |
| Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247-4253, 2009 | 2481 | 2009 |
| Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis H Hirata, A Takahashi, S Kobayashi, S Yonehara, H Sawai, T Okazaki, ... The Journal of experimental medicine 187 (4), 587-600, 1998 | 698 | 1998 |
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib DB Costa, S Kobayashi, SS Pandya, WL Yeo, Z Shen, W Tan, KD Wilner Journal of Clinical Oncology 29 (15), e443-e445, 2011 | 675 | 2011 |
| EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications H Yasuda, S Kobayashi, DB Costa The lancet oncology 13 (1), e23-e31, 2012 | 645 | 2012 |
| Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ... Science translational medicine 5 (216), 216ra177-216ra177, 2013 | 602 | 2013 |
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations DB Costa, B Halmos, A Kumar, ST Schumer, MS Huberman, TJ Boggon, ... PLoS medicine 4 (10), e315, 2007 | 582 | 2007 |
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway KSH Nguyen, S Kobayashi, DB Costa Clinical lung cancer 10 (4), 281-289, 2009 | 579 | 2009 |
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies H Ji, D Li, L Chen, T Shimamura, S Kobayashi, K McNamara, U Mahmood, ... Cancer cell 9 (6), 485-495, 2006 | 544 | 2006 |
| Differential effects of gefitinib and cetuximab on non–small-cell lung cancers bearing epidermal growth factor receptor mutations T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, ... Journal of the National Cancer Institute 97 (16), 1185-1194, 2005 | 406 | 2005 |
| Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance GN Naumov, MB Nilsson, T Cascone, A Briggs, O Straume, LA Akslen, ... Clinical Cancer Research 15 (10), 3484-3494, 2009 | 388 | 2009 |
| An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor S Kobayashi, H Ji, Y Yuza, M Meyerson, KK Wong, DG Tenen, B Halmos Cancer research 65 (16), 7096-7101, 2005 | 320 | 2005 |
| EGFR-mutated lung cancer: a paradigm of molecular oncology Z Zhang, AL Stiegler, TJ Boggon, S Kobayashi, B Halmos Oncotarget 1 (7), 497, 2010 | 249 | 2010 |
| Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors S Kobayashi, HM Canepa, AS Bailey, S Nakayama, N Yamaguchi, ... Journal of Thoracic Oncology 8 (1), 118-122, 2013 | 227 | 2013 |
| Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells Z Zhang, S Kobayashi, AC Borczuk, RS Leidner, T LaFramboise, ... Carcinogenesis 31 (4), 577-586, 2010 | 220 | 2010 |
| Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib DB Costa, KSH Nguyen, BC Cho, LV Sequist, DM Jackman, GJ Riely, ... Clinical cancer research 14 (21), 7060-7067, 2008 | 218 | 2008 |
| Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers DB Costa, S Kobayashi, DG Tenen, MS Huberman Lung Cancer 58 (1), 95-103, 2007 | 216 | 2007 |
| Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance T Shimamura, D Li, H Ji, HJ Haringsma, E Liniker, CL Borgman, ... Cancer research 68 (14), 5827-5838, 2008 | 200 | 2008 |
| Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer H Yasuda, LL de Figueiredo-Pontes, S Kobayashi, DB Costa Journal of Thoracic Oncology 7 (7), 1086-1090, 2012 | 188 | 2012 |
| Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes PA VanderLaan, D Rangachari, SM Mockus, V Spotlow, HV Reddi, ... Lung cancer 106, 17-21, 2017 | 185 | 2017 |
